Should Atara Bio’s Stock Volatility Consider Any Valuation at All on Multiple Sclerosis?24/7 Wall Street • 05/26/20
Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 05/18/20
Atara Biotherapeutics Inc (ATRA) CEO Pascal Touchon on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Turnaround In Progress: Key Takeaways From Atara Biotherapeutics' Q3 Earnings CallSeeking Alpha • 11/14/19
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/09/19
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019GlobeNewsWire • 09/13/19
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/09/19